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Brain tumours are among the most feared of all forms of 
cancer. More than two-thirds of adults diagnosed with 
glioblastoma — the most aggressive type of brain cancer 
— will die within 2 years of diagnosis1,2. Brain cancers 
are also the most common and most lethal of all paedi-
atric solid tumours3. Furthermore, children with these 
tumours who survive and enter adulthood will often be 
affected by the long-term consequences of exposing the 
developing brain to medical interventions, including 
surgery, radiotherapy and/or chemotherapy4,5.
Brain tumours have proved challenging to treat, 
largely owing to the biological characteristics of these 
cancers, which often conspire to limit progress. First, 
by infiltrating one of the body’s most crucial organs, 
these tumours are often located beyond the reach of 
even the most skilled neurosurgeon. These tumours are 
also located behind the blood–brain barrier (BBB) — 
a system of tight junctions and transport proteins that 
protect delicate neural tissues from exposure to factors 
in the general circulation, thus also impeding exposure 
to systemic chemotherapy6,7. Furthermore, the unique 
developmental, genetic, epigenetic and microenviron-
mental features of the brain frequently render these 
cancers resistant to conventional and novel treatments 
alike8–10. These challenges are compounded by the rarity 
of brain tumours relative to many other forms of cancer, 
which limits the level of funding and interest from the 
pharmaceutical industry and attracts a relatively small 
and fragmented research community.
To begin to address these issues and improve the out-
comes of patients with brain tumours, Cancer Research 
UK (CRUK) convened an international panel of brain 
cancer researchers with interests in neurobiology, pre-
clinical tumour modelling, genomics, pharmacology, 
drug discovery and/or development, neuropathology, 
neurosurgery, imaging, radiotherapy and medical onco-
logy, with the task of identifying the most important 
challenges that must be overcome if we are to eventu-
ally be in the position to cure all patients with a brain 
tumour. In this Position Paper, we summarize seven key 
challenges identified by the panel that should serve as 
the foci for future research and investment (Fig. 1). Each 
of these challenges is worthy of extensive discussion and 
review, which are beyond the scope of this manuscript. 
Therefore, we highlight these challenges as a ‘call-to-
arms’, summarizing the nature and importance of each 
challenge rather than providing an exhaustive review of 
the current level of understanding.
Challenge 1: redesign research pipeline
Clinical trials have yet to reveal an effective therapy for 
most brain tumours. This harsh reality stems, in part, 
from an incomplete understanding of brain tumour 
biology and the existence of a disconnect between 
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preclinical drug development and rigorous testing in the 
clinic. Each element of the brain tumour research pipe-
line, from basic neurobiology to clinical trials, requires 
careful scrutiny and increased investment, although 
the development of an overarching strategy that facili-
tates and promotes interdisciplinary research is equally 
important (Fig. 1). This strategy would bring an end to 
the previous ‘siloed’ organization of working practices, 
in which basic and clinical researchers performed their 
studies independently and collaborated only when labo-
ratory research was judged to be ready for the clinic or 
when the laboratory is engaged to understand the rea-
sons why a promising drug failed to achieve the expected 
level of efficacy in clinical trials. Much deeper, longitu-
dinal collaboration is essential in order to drive progress 
as rapidly as possible.
Nascent attempts to unify the brain tumour research 
pipeline are underway. The international paediatric 
brain tumour community has demonstrated remark-
able levels of collaborative activity over many years and 
is now working to discover and define the genomic 
subtypes of paediatric brain tumours and form multi-
disciplinary teams in order to design preclinical studies 
that better inform the design of clinical trials11,12. However, 
the community must go further, by forming interna-
tional collaborations that extend beyond the borders 
of traditional research disciplines and by engaging 
the entire breadth of expertise available within the 
biological and physical sciences (see Challenge 2). 
Such congregations of experts could provide a more 
comprehensive understanding of the workings of the 
brain and how these processes are subverted during 
malignant transformation.
The community should also explore innovative meth-
ods of designing and delivering clinical trials. Interest 
among the brain tumour research community in the use 
of adaptive trial designs is particularly welcomed13,14. 
Such trials could provide prospective opportunities to 
modify ongoing studies and integrate the investigation 
of new hypotheses as data are accumulated and analysed 
(Fig. 2). This approach has distinct advantages over the 
less flexible, traditional trial designs, which are typi-
cally designed to test one or two primary hypotheses, 
typically in heavily pretreated patients over a number of 
years. However, several hurdles must be overcome before 
novel trial designs can be implemented successfully, 
including identifying a cadre of rational therapies to feed 
into these new trials; developing robust biomarker-based 
patient selection criteria; constructing systems that ena-
ble the provision of real-time, in-trial, biomarker and 
end point data; and formulating optimal mechanisms 
of generating and sharing complex research data among 
centres worldwide (Fig. 2). Notwithstanding these chal-
lenges, improving the current approach to clinical trials 
is an urgent objective for the community. In the context 
of small, genomically defined patient subgroups, inter-
national collaborative clinical trials are crucial. A com-
prehensive review of the current logistical, regulatory 
and financial hurdles that inhibit the initiation of such 
trials is therefore warranted.
Greater integration of research disciplines will also 
require a change in the current research culture. The 
principal metrics used to reward success in most aca-
demic environments are focused on competitive activi-
ties, such as publication in high-impact journals and the 
acquisition of grant funding. These metrics have some 
value in enabling the assessment and quantification of 
the extent of innovative thought and discovery, although 
they arguably also work against the development of the 
deeper levels of collaborative activity that will ultimately 
be required to cure patients with brain tumours. This 
change in academic culture must go beyond a cursory 
recognition of the value of ‘team science’. Rather, akin to 
the complex and multidisciplinary groups that operate 
in the pharmaceutical industry, new reward and pro-
motion structures should be developed for laboratory 
and clinical researchers alike that inspire and encour-
age their participation in collaborative academic brain 
tumour research.
Challenge 2: use neuroscience research
We now have a considerable level of understanding 
of the cellular hierarchies and signals that generate 
and maintain brain activity in the absence of cancer15. 
Specialized glial cells serve as neural stem cells (NSCs) 
in both the embryonic and adult brain, in which they 
reside in neurogenic niches and produce daughter cells 
that differentiate into neurons, astrocytes and oligoden-
drocytes (Fig. 1). These niches also include supporting 
cells and secreted factors that are critical for the close 
regulation of both NSC self-renewal and the early stages 
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of daughter cell differentiation: an intimate relationship 
between NSCs and blood vessels seems to be especially 
important in the neurogenic niche16.
Several lines of evidence suggest that brain tumours 
arise within, or are driven by, cells that recapitulate the 
neurogenic niche (Fig. 3). Stem-like cells have been iso-
lated from paediatric and adult brain tumours17–19, and 
brain tumours have been shown to contain malignant 
niches that seem to recapitulate the micro-architectural 
features and signalling properties of the nonmalignant 
neurogenic niche20,21. Recurrent mutations in brain 
tumours can also perturb the signalling pathways 
that regulate brain development12, and subgroups 
of brain tumours have been shown to contain the 
transcriptomes and epigenomes of their originating 
parental NSCs that generated these tumours in the 
mouse brain22–29.
Evidence that brain tumours are a consequence 
of aberrant brain development or repair under-
scores the importance of closer integration between 
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Fig. 1 | Challenges to curing primary brain tumours at different stages of tumour development. The nonmalignant 
cellular composition of the ventricular–subventricular zone includes neural stem cells that divide and produce 
transit-amplifying cells. Transit-amplifying cells give rise to migratory neuroblasts90. Ependymal cells are also present in 
the neural stem cell niche. The niche is intimately associated with blood vessels and might also communicate with other 
cell types, including microglia and astrocytes. Malignant transformation of neural stem cells presumably leads to the 
premalignant expansion of transit-amplifying cells and migratory neuroblasts as the nonmalignant hierarchy begins to 
transform. This unregulated hierarchy generates the malignant brain tumour. As these lesions are treated, tumour cells 
are killed, with the ultimate goal of eventual cure. The blue panels below these cartoons denote the focus of key research 
questions at each stage, from nonmalignant brain tissue to the development of cancer and remission following 
successful treatment. The green panels depict how the seven challenges to progress relate to these specific stages of 
disease development.
neurobiological and cancer research; however, clear 
examples of such collaborations are rare. Only ~1% 
(US$260 million) of the $21 billion invested in neuro-
science research by the US NIH in 2018 is aimed specif-
ically at brain tumour research. Furthermore, although 
the PubMed database currently contains ~320,000 and 
198,000 articles on neuroscience and brain tumour 
research, respectively, only 6,000 (~2% and ~3.5%, 
respectively) overlap. These observations are crude indi-
cators of the level of interaction, but they suggest that 
the brain tumour research community is not capitalizing 
fully on the available research data. An increased focus 
on areas of common interest, such as immune dysregu-
lation in patients with cancer and in those with demen-
tia, should drive joint funding initiatives and ultimately 
result in progress for patients30,31.
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Fig. 2 | Suggested general outline of a platform approach to designing clinical trials for the assessment of brain 
tumour therapies. Patients with different molecular subtypes of a specific type of brain tumour (represented as blue,  
red and green figures) are enrolled into the trial. Patients in the control group receive the optimal standard of care.  
New treatments can then be tested as comparators in groups A and B. Following a defined period of treatment, the 
responses of patients in these groups are compared with those of patients in the control group. Responding patients are 
represented by bold colours; nonresponding patients are coloured grey. In this example, new treatment B produced a 
biased favourable response in patients with a single disease subtype (blue figures) relative to the control treatment. No 
advantage of new treatment A is observed relative to the control treatment. Therefore, in the next phase of the study , the 
new treatment A group is discontinued, while the new treatment B arm proceeds, with enrichment for patients with 
tumours of the ‘blue’ subtype. The control group continues with randomized recruitment of patients with all disease 
subtypes. The success of this approach is dependent upon addressing the key challenges summarized in the thought 
bubbles emerging at each stage of the trial. Many of these challenges are yet to be addressed in patients with brain tumours.
Challenge 3: understand the TME
A thorough understanding of the properties and 
functions of the tumour microenvironment (TME) is 
required in order to obtain a complete understanding of 
brain tumour biology and treatment9,32 (Fig. 4). As dis-
cussed with regard to Challenge 2, closer interactions 
with scientists investigating nonmalignant brain diseases 
will be especially important to this effort. Over many 
decades, research groups studying neurodegeneration 
and other nonmalignant brain diseases have generated a 
considerable level of understanding of the biology of the 
extracellular matrix, of specific brain-resident cellular 
populations (such as microglia, astrocytes and neurons) 
and of blood vessels (including those forming the BBB) 
that comprise the TME.
The immune and vascular components of the TME 
are likely to have particular relevance for improving the 
treatment of brain tumours6,33. For example, the discov-
ery of the immune or glymphatic system of the brain and 
evidence that immunotherapies are effective treatments 
for an increasing number of cancers have prompted stud-
ies of the efficacy of such therapies in patients with brain 
tumours31,34–36. The major myeloid cell populations of 
the brain TME comprise macrophages and microglia — 
together referred to as tumour-associated macrophages 
(TAMs)37,38. Glioblastoma cells stimulate TAMs to pro-
duce immunosuppressive, tumour-promoting cytokines 
and enhanced apoptosis of T cells39. Glioblastoma cells 
can also inhibit the production of immunostimulatory 
cytokines and activate the recruitment of regulatory 
T cells, thus inhibiting antitumour immune responses40. 
These data suggest that inhibiting the activity of TAMs 
might provide therapeutic benefit in patients with brain 
tumours, although the clinical reality is likely to be more 
complex. Research conducted over the past decade sug-
gests that re-educating TAMs to adopt phenotypes that 
are likely to prevent or inhibit the progression of brain 
tumours might be more effective than depleting all TAM 
populations32,41. A range of additional immune-based 
therapies are also currently in development, includ-
ing vaccines, cellular therapies (such as chimeric anti-
gen receptor (CAR) T cells) and immune-checkpoint 
inhibitors9,31,34,40–42.
Regardless of the type of immunotherapy that is being 
developed, several key challenges must be addressed 
if we are to deploy these agents effectively in the treat-
ment of brain tumours (Fig. 4). Once again, a better 
understanding of tumour biology will be important to 
the selection of patients who are most likely to benefit 
from therapies and to improve the level of understand-
ing of treatment-related toxicities (see Challenge 1). 
Addressing these challenges will not be straightforward 
for immunotherapies, not least because even the impre-
cise predictors of a response to immune-checkpoint 
inhibition in other cancers, such as tumour mutational 
burden and/or DNA methylation, remain to be proved 
in patients with brain tumours43. Furthermore, the iden-
tity of the optimal targets of other immunotherapies, 
such as CAR T cells, which might be patient specific, 
also remains unclear. Other important and unanswered 
questions surrounding the use of immunotherapies 
in patients with brain tumours include the degree to 
which the BBB will impede the access of cellular and 
molecular immunotherapies to tumours; whether 
immunotherapies will synergize with or counteract 
the effects of existing treatments, such as temozolo-
mide, steroids and/or radiotherapy; and the type and 
severity of neurological adverse effects associated with 
immunotherapies and how best to prevent, monitor 
and manage these. Thus, although immunotherapy 
holds great promise as a new therapeutic approach for 
the treatment of patients with brain tumours, many 
aspects of the unique immuno logical and microenviron-
mental status of the brain present challenges that need 
to be overcome in order to develop and validate these 
therapies efficiently9.
As previously alluded to, the BBB is a major hurdle 
to the successful treatment of brain tumours44. This 
dynamic structure of tight junctions and molecular 
pumps comprises endothelial, ependymal and tanycytic 
cells that communicate with other brain cells and with 
circulating immune cells45–48. Single-cell transcriptomics 
has revealed a remarkable level of regional hetero geneity 
along the arteriovenous axis of the BBB, including 
a seamless continuum of endothelial cells versus a 
Nature reviews | CliniCal OnCOlOgy
C o n S e n S u S  S tat e m e n t
Ependymal 
cell
Transit-
amplifying cell
Migratory
neuroblast
Malignant migratory
neuroblast
Neural 
stem cell
Blood
vessel
Malignant transit-
amplifying cell
Paracrine control 
of brain tumour 
stem cells?
Malignant brain 
stem cell niche?
Aberrant brain 
stem cell niche?
Format and 
control of brain 
tumour hierarchy?
Malignant neural 
stem cell
Fig. 3 | The cellular origins of brain tumours. Brain tumours are thought to arise from  
a transformed and malignant brain tumour hierarchy generated from transformed 
neuronal stem cells. Nonmalignant and malignant stem cells in the brain are believed to 
reside in perivascular niches formed by the blood vessels of the brain. Unaddressed key 
research questions that could provide a better understanding of brain tumour 
development and treatment are shown in the thought bubbles.
punctuated continuum of mural cells49. These insights 
could prove important in determining the functionality 
of the BBB in tumours located in different regions of 
the brain.
Discrete subtypes of brain tumours might also alter 
the BBB (Fig. 4). In this regard, the WNT subtype of 
medulloblastomas, which are highly sensitive to treat-
ment, has been shown to secrete WNT antagonists that 
‘re-educate’ the BBB, thus causing it to adopt a pheno-
type that is highly permeable to systemic chemother-
apy6. Similarly, the therapeutic response of gliomas to 
temozolomide might be improved by use of this agent 
in combination with small-molecule inhibitors of WNT 
signalling33. Greater research efforts should be invested 
in cataloguing the integrity and other alterations of the 
BBB in each brain tumour subtype. This information 
might enable the more widespread use of systemic ther-
apies that are currently regarded as BBB non-penetrating 
in those tumours that lack an intact BBB and support 
the use of WNT inhibitors and other approaches to 
enhance the delivery of chemotherapy to those tumours 
in which the BBB is intact50.
Challenge 4: develop preclinical models
The limited progress made in the treatment of brain 
tumours relates, in part, to the inaccuracy of preclini-
cal models that have thus far failed to consistently show 
responses to agents with therapeutic activity in patients. 
Preclinical drug development pipelines that enable the 
accurate prediction of effective drugs are especially 
important for rare cancers, including brain tumours, 
owing to the low numbers of patients available for 
www.nature.com/nrclinonc
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Fig. 4 | The brain tumour microenvironment and treatment. Brain tumours typically comprise a complex mixture of 
malignant cells and a great variety of nonmalignant cells. These include immune, vascular and nonmalignant brain cells,  
all of which are able to communicate with malignant cells and contribute to the development and progression of cancer. 
These features also form a key part of the response of a tumour to treatment. Key research questions focused on 
understanding how these elements affect tumour biology and responses to treatment are shown in the thought bubbles. 
BBB, blood–brain barrier ; TAM, tumour-associated macrophage.
participation in clinical research12,51. Current pipelines 
are limited in their ability to identify new, more effec-
tive treatments of brain tumours for several reasons: they 
typically involve poorly characterized in vitro systems 
or subcutaneous tumour xenografts, rather than more 
accurate orthotopic models of brain tumours; they do 
not enable the assessment of benefit from new treat-
ments in terms of survival relative to that provided by 
the existing combinations of neurosurgery, radiotherapy 
and/or chemotherapy; and finally, they usually lack rigo-
rous characterization of other clinically important fea-
tures, such as those of the BBB. Thus, curing all patients 
with a brain tumour will require a new approach that 
leverages an improved understanding of neuroscience 
and brain tumour biology to develop and deploy more 
accurate preclinical models.
A better understanding of the processes that drive 
the development and progression of brain tumours 
should promote the development of more accurate 
genetically engineered mouse models (GEMMs) and 
patient-derived xenografts (PDXs). We recommend 
that the brain tumour community maintains a central-
ized catalogue of all existing and newly developed pre-
clinical models that have been subjected to a minimum 
agreed set of rigorous histological, genomic and imaging 
evalu ations. Models from this catalogue should be made 
readily available and would provide the community with 
universally accessible, validated models that closely 
mimic the characteristics of human tumours. Initiatives 
such as the ITCC Paediatric Preclinical Proof of Concept 
Platform are already underway, with the intention of 
creating such a resource.
In addition to minimum standards of model charac-
terization, the community should also adopt minimum 
standards for preclinical studies, thus enabling more effec-
tive comparisons of the results of different studies (Fig. 5). 
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Fig. 5 | Stratified approaches to the development of new treatments for patients with brain tumours. Schema 
depicting pathways for improvements in the preclinical development of new treatments for subsets of patients with brain 
tumours of distinct molecular and/or clinical subtypes (represented by different colours). This approach should include 
both patient-derived xenografts (PDXs) and genetically engineered mouse models (GEMMs) that accurately reflect the 
principle molecular and/or clinical subtypes. In order to provide the optimal level of clinical relevance, these models must 
also involve an assessment of responses to conventional combination therapies. These existing treatments could be 
included in adaptive preclinical trials designed to test novel treatments and inform the ultimate clinical trial design.
Of particular note, although patients with brain tumours 
receive complex, multimodality therapy, mice in pre-
clinical studies typically receive monotherapies that are 
rarely comparable to the standard of care for the malig-
nancy that is being modelled. Thus, efforts to estab-
lish preclinical ‘mouse hospitals’, in which potential 
new therapies are tested in the context of combination 
with neurosurgery, fractionated radiotherapy and/or 
conventional chemotherapy, should become the new 
standard11. Researchers with access to such preclinical 
hospitals should also perform robust pharmacokinetic 
(with particular attention to BBB penetration), pharma-
codynamic and biomarker (tumour, liquid biopsy 
and imaging) studies for novel agents, thus maxi-
mizing the speed and likelihood of success of clinical 
translation (Fig. 5).
The failure of many drugs to penetrate the BBB to 
any clinically meaningful extent is an important reason 
for the poor treatment responses of patients with brain 
tumours to systemic therapies52. Functional imaging 
studies in particular can provide evidence of early treat-
ment responses, although a failure to detect a response 
cannot distinguish between a drug that is ineffective 
and one that simply does not cross the BBB. Contrast 
enhancement of tumours on MRI, using various agents, 
can reveal disruption of the BBB, for example, following 
ultrasonography-mediated opening of the BBB53; how-
ever, this approach does not provide direct evidence of 
drug delivery. More direct evidence can be provided by 
observing tumour accumulation on PET imaging of 
drugs labelled with a positron-emitting isotope, such as 
[methyl-11C] temozolomide in patients with gliomas54. 
However, conjugating all new drugs with such isotopes 
— particularly with 11C, which will not perturb drug 
chemistry and thus drug–target interactions but has 
a sufficiently short half-life (20.3 minutes) — would 
be a formidable undertaking. Thus, the community 
should agree on acceptable preclinical and clinical 
standards for demonstrating successful drug delivery to 
brain tumours.
In addition to being grown as PDXs, patient-derived 
brain tumour cells can be consistently and successfully 
encouraged to propagate under NSC culture condi-
tions as organoids55,56. These short-term culture sys-
tems have enormous potential for studying interactions 
between different cells and drug sensitivities and for 
interrogation using genome-wide interference and/or 
editing techniques20,55–58. Preclinical pipelines that 
deploy these novel screening approaches, together 
with the use of matched GEMMs and PDX models 
(ideally in humanized mice), should provide a more 
comprehensive and more accurate means of delivering 
optimized drugs and their associated biomarkers into 
clinical trials11.
Preclinical and clinical research efforts to evalu-
ate the value of new treatments, relative to that of the 
conventional treatments of brain tumours, should also 
consider re-evaluating some long-established treat-
ment approaches that might be of questionable value. 
For example, corticosteroids, such as dexamethasone, 
continue to be used perioperatively and might be con-
tinued throughout subsequent treatment. The original 
reasons for using dexamethasone in this way probably 
reflect antiproliferative activity that confers protection 
of nonmalignant cells from radiotherapy-induced and 
chemotherapy-induced genotoxic stress. However, both 
clinical data and preclinical data from mouse models 
suggest that corticosteroids might decrease the effec-
tiveness of treatments and shorten the survival dura-
tions of patients with glioblastoma. Thus, greater efforts 
should be invested in identifying alternative agents, on 
the basis of robust preclinical and clinical evidence, 
such as anti-VEGF agents for the treatment of brain 
tumour-associated oedema59.
Challenge 5: drugging complex cancers
The so-called omics revolution is providing a compre-
hensive view of the genomes, epigenomes and transcrip-
tomes of brain tumours; this additional information has 
enabled the segregation of histologically similar subsets 
of tumours into clinically and molecularly distinct sub-
groups. However, despite a few notable exceptions, such 
as inhibitors of mTOR or BRAF in selected patients60,61, 
genomics has yet to deliver on the promise of identi-
fying new therapeutic targets in patients with brain 
tumours. Discovering new treatments of brain tumours 
will require a much deeper level of understanding of 
the biology of potential drug targets, combined with the 
application of cutting-edge drug discovery approaches 
to inhibit these targets.
Progress in drug development will not come easily. 
Alterations identified in brain tumours in the past dec-
ade include poorly understood targets that are frequently 
regarded as undruggable, including amplification of 
genes encoding transcription factors, such as MYC 
and MYCN; gene translocations, such as FGFR–TACC and 
C11OF95–RELA27,62; oncogene ‘enhancer hijacking’, for 
example, by GFI1 (reF.63); and mutated histones, such as 
H3F3A and HIST1H3B variants64,65. Furthermore, these 
alterations exist in a shifting landscape of tumour hetero-
geneity, in which the populations of clones carry ing each 
alteration fluctuate as the disease evolves in response 
to therapy66,67. This clonal evolution means that the pro-
portion of tumour cells carrying a specific drug target 
can vary markedly during the course of disease, thus 
complicating efforts to target specific alterations. This 
hetero geneity can be measured in terms of mutational 
load, epigenetic alterations, rewiring of transcriptional 
circuits and microenvironmental influences and is widely 
considered to underpin the diversity of responses to 
treatment. The serial analysis of tumour biology using 
additional measures, such as advanced metabolic imag-
ing and analyses involving serial sampling of circulating 
tumour DNA, is discussed with regard to Challenge 6 
and might provide a more complete and accurate picture 
of tumour evolution.
Although daunting, the data provided by these novel 
approaches reflect an important principle that must be 
adopted by brain tumour researchers and clinicians — 
the notion that brain tumours are monogenetic and 
monoclonal must be dispelled. Comprehensive map-
ping of genomic evolution before, during and following 
treatment, including the use of single-cell sequencing 
approaches, should be used to better identify and 
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prioritize treatment targets68,69. This objective will be 
best achieved in the context of prospective clinical 
trials, in which molecular imaging and other diag-
nostic approaches can be used to provide real-time 
assessments of disease evolution70. Prioritized targets 
should also be interrogated using approaches, such 
as deep mutational scanning, that can reveal infor-
mation on the intrinsic properties of proteins and 
their function and how this changes with mutation71. 
Reverse translation efforts involving detailed mech-
anistic studies after a clinical trial of appropriately 
prioritized targets should include functional studies 
that enable the accurate definition of target function 
in tumours. Such serial analyses will likely be complex 
and resource-intensive and are probably best organ-
ized as part of a community-wide approach. This 
approach might be promoted in several ways: develop-
ment of international tumour subtype-specific trials; 
the widespread availability of brain tumour stem cell 
banks (such as the UK glioma cellular genetics resource 
(GCGR), the human glioblastoma cell culture (HGCC) 
resource in Sweden and the Stand Up to Cancer (SU2C) 
Canada Cancer Stem Cell Dream Team); established 
efforts to understand complex cancer targets (such as 
the US National Cancer Institute RAS Initiative); and 
closer collaborations with industry.
Challenge 6: precision medicine
The current classifications of brain tumours are based 
primarily on microscopic morphology and immuno-
histochemistry72. This approach enables the broad 
characterization of tumour type and a certain level 
of prognostication, although it fails to capitalize on 
the wealth of clinically relevant insights produced by the 
genomic subtyping of brain tumours. This dilemma is 
exemplified by medulloblastoma and ependymoma, 
both of which consist of clinically relevant subtypes 
with discrete cells of origin, driver mutations and global 
transcriptomic and epigenomic patterns that are yet to 
be incorporated into the WHO classification of central 
nervous system tumours10,12,72–75.
Concerns that genome-wide classification tools 
might prove impractical for the routine diagnosis of 
brain tumours have been dispelled by the successful 
large-scale methylome subtyping of formalin-fixed, 
paraffin-embedded tumours75,76. Therefore, the chal-
lenge to the brain tumour community is not whether 
but how to deploy diagnostic genomic profiling. In the 
UK, the centralization of genomic profiling through 
the National Health Service provides an enormous 
opportunity to begin this process at a population level. 
In doing so, it will be important to note that not all brain 
tumours are created equally: paediatric medulloblasto-
mas and ependymomas comprise robust subgroups with 
distinct characteristics. However, the degree of diagnos-
tic separation of other brain tumours, including gliomas 
in adults, is less clear.
The genomic classification of brain tumours will 
increase the level of diagnostic precision that is cur-
rently achievable, although intratumoural hetero-
geneity and the often limited amounts of tumour 
material available for analysis are likely to confound the 
accurate diagnosis of some tumours68,77. Therefore, the 
research community should aim to urgently investigate 
the use of more advanced imaging techniques, such as 
13C-hyperpolarized MRI, radiomics and sequencing of 
cell-free DNA obtained from plasma and/or cerebro-
spinal fluid, as ancillary approaches to the diagnosis 
and classification of brain tumours70,78–80. The challenge 
of validating and combining these new diagnostic 
modalities is enormous but also holds the potential to 
greatly improve the accuracy of brain tumour classifi-
cation. Implementation of such approaches might also 
improve the assessment of novel therapies as part of 
the federal drug approval process. In this regard, the 
current standards, such as the Response Assessment in 
Neuro-Oncology criteria81, which describe complete and 
partial drug responses, are of limited value for assess-
ing new treatments of slow-growing tumours, such as 
low-grade glioma. Early molecular and/or metabolic 
responses that are predictive of ultimate clinical bene-
fit might, therefore, provide a more accurate means of 
evaluating the efficacy of treatments.
Once validated, new classification tools, such as those 
outlined above, must be adopted within the WHO guide-
lines in order to enable use by the wider community. 
A comprehensive strategy to achieve this goal should 
formally include genomic metrics, such as transcrip-
tomic analysis, in WHO diagnosis and classification 
schemes; involve appropriate training of experienced 
and newly qualified pathologists in genomic methodolo-
gies; be accompanied by appropriate levels of investment 
in the resources (both capital and personnel) needed to 
deliver genomic assays routinely in diagnostic pathology 
labs; and incorporate standardized genomic characteri-
zation within both conventional and clinical trial man-
agement strategies. Histology will always have a place 
in the diagnosis of patients, although only when used in 
concert with advanced molecular and imaging-based 
diagnostics will this provide a comprehensive prediction 
of tumour behaviour.
In addition to developing advanced diagnostic 
approaches, we must also learn how best to integrate 
these rich data streams if they are to revolutionize the 
treatment of patients with cancer (Fig. 5). Continual, 
iterative and integrated analysis of these complemen-
tary and complex data streams should be made possible 
by machine learning, artificial intelligence and/or other 
mathematical and computational approaches. This will 
require a concerted effort to invent and deploy new 
analytical approaches and visualization technologies in 
order to generate a single flow of information that travels 
with a patient throughout his or her treatment journey, 
enabling better-informed management decisions and 
guiding the patient towards the maximum opportu-
nity for cure (Fig. 6). Reporting the clinically relevant 
findings from such large-scale data sets to health-care 
professionals and patients will require a multidiscipli-
nary approach, supported by appropriate information 
technology infrastructure, genetic counsellors, medical 
geneticists and clinical scientists. This longitudinal and 
integrated approach will also enable the development 
of the next generation of adaptive precision medicine 
clinical trials.
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Challenge 7: reduce treatment for some
Certain brain tumours, particularly those arising in chil-
dren, can be cured with aggressive surgery, radiotherapy 
and chemotherapy, although these cures often carry a 
considerable cost, particularly for young children who 
have lifelong neurocognitive and endocrine adverse 
effects4,82. Reducing the intensity of treatment in children 
with other cancers, such as acute lymphoblastic leukae-
mia, has enabled a reduction in the incidence of adverse 
effects while maintaining high cure rates; however, 
this approach has proved challenging to implement in 
patients with brain tumours, the majority of whom have 
disease progression following surgery alone. Identifying 
which patients might be cured with less-intense adju-
vant radiotherapy and chemotherapy and to what extent 
the intensity of these modalities can be safely reduced 
remains a major challenge.
Medulloblastomas provide a clear example of how 
a detailed understanding of tumour biology can guide 
adjustments of treatment intensity. Historical attempts 
to limit the damaging effects of craniospinal radio-
therapy on the developing brain by reducing the radi-
ation dose have failed, largely owing to an inadequate 
understanding of medulloblastoma biology, which 
precluded the accurate selection of patients with truly 
low-risk disease83–85. A breakthrough was achieved 
with the recognition that almost all patients with the 
WNT subtype of medulloblastoma are cured12. This 
discovery has led to a series of highly selective ongo-
ing studies testing reduced-intensity radiotherapy in 
patients with this disease subtype (NCT02724579, 
NCT02066220, NCT02212574 and NCT01878617). 
Evidence that WNT-subtype tumours (but not other 
forms of medullo blastoma) lack a BBB and are there-
fore remarkably vulnerable to systemic chem otherapy 
provides an explanation for the curability of these 
tumours, thus opening further options for alternatives 
to radiation-based treatments6. Paediatric low-grade 
gliomas provide another example of how molecularly 
guided treatments (such as inhibitors of activated BRAF 
and MEK) are enabling reductions in radiation dose86,87. 
Studies involving patients with other brain tumours 
are likely to identify similar approaches for the rational 
de-escalation of therapy.
A comprehensive approach to preventing and ame-
liorating the adverse effects associated with long-term 
treatment should include prospective functional and 
patient-reported outcome measures, as well as inno-
vative predictive assessments of risk. Novel ways of 
supplementing these data are also emerging in the 
form of genetic polymorphisms and somatic genomic 
characteristics that might predict the risk of subsequent 
intellectual disability and/or hearing loss88,89.
Conclusions
The past 15 years have witnessed a revolution in our 
understanding of cancer. The integration of genomic and 
developmental biology has shown that morphologically 
similar cancers comprise discrete subtypes, driven by 
different genetic alterations, which likely arise from dis-
tinct cell lineages. These data help to explain why cancers 
once regarded as histologically homogeneous diseases 
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Fig. 6 | a precision medicine approach to the  
treatment and management of patients with  
brain tumours. Serving as a ‘biological prism’,  
the use of artificial intelligence (AI) and machine  
learning (ML) approaches should enable the  
integration of separate data streams at critical points  
in the patient journey , providing an unprecedented  
level of comprehensive decision-making to guide  
the selection of the most appropriate treatment and 
support the management of patients with brain  
tumours. The knowledge gained through the 
management of each patient should be analysed 
iteratively over time, enabling constant refinement  
and improvements in clinical decision-making.  
ctDNA , circulating tumour DNA.
have a discrepant range of characteristics. Improved 
understanding is also leading to the development of 
completely new treatment approaches for cancer, such as 
immunotherapies, and novel ways to test such therapies, 
such as adaptive trial designs. However, the successes 
achieved with these improvements have not occurred 
equally across all forms of cancer. Of particular note, the 
treatment of most childhood and adult brain tumours 
is at an impasse, with no new, more effective therapies 
being developed in the past 30 years. Thus, all available 
evidence suggests that the current preclinical and clin-
ical research approaches to curing brain tumours are 
ineffective.
Herein, we have summarized seven major challenges 
to progress that must be overcome if we are to produce 
the sea change in brain tumour therapy that has long 
been awaited by patients and their families. Some of 
these challenges might seem to be self-evident; however, 
each will require a profound change in research and clin-
ical practice and investment. In order to truly redesign 
the brain tumour research and treatment pipeline and 
to leverage the full spectrum of neuroscience research, 
modest improvements in the level of interdisciplinary 
collaborations among otherwise siloed research groups 
will not be sufficient. We envisage a much more substan-
tial congregation of experts and infrastructure, focused 
on the task of curing brain tumours. This call reflects 
the need to practise brain tumour research differently 
and to identify, convene and support teams of scientists 
and clinicians who focus specifically and urgently on the 
need to improve the lives of patients with brain tumours. 
This approach must be different from the largely ad hoc 
and predominantly poorly structured brain tumour 
collaborations and programmes that currently exist in 
most academic centres. The harsh reality is that the cur-
rent efforts at various universities and aligned clinical 
environments around the world have failed to adequately 
improve the understanding and treatment of patients 
with brain tumours. Nevertheless, this approach would 
probably be easiest to implement within the context 
of existing academic settings in order to engage with 
and closely incorporate disciplines not traditionally 
involved in brain tumour research, such as engineering, 
chemistry, physics and mathematics.
As we seek to better understand the role of the TME 
and aim to develop more predictive preclinical model 
systems, we need to take a long, hard look at the current 
model systems. Many of these clearly do not adequately 
reflect all the nonmalignant and malignant cell types 
that compose brain tumours and have failed to accu-
rately predict treatments that will be effective for testing 
in clinical trials. Only systems that are proven to model 
clinically relevant aspects of tumour biology should be 
used as evidence to guide the initiation of clinical trials. 
Furthermore, through reverse translation, we should 
refine the use of or entirely remove models that fail to 
predict clinical efficacy.
Concerns relating to safety and patient accepta-
bility limit the ability to obtain repeat biopsy samples 
from brain tumours in most patients, thus preventing 
longitudinal studies of tumour biology and treatment 
response and the deployment of a precision medicine 
approach. The use of liquid biopsies and advanced 
imaging approaches should be explored immediately 
to provide additional approaches to determine tumour 
response earlier in the course of treatment. Finally, 
the challenge most likely to yield patient benefit in the 
immediate future will be the use of advanced stratifica-
tion approaches to reduce the risk of treatment-related 
toxicities, especially among children.
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